Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients
Main finding · All-cause mortalityResult — go to the resultAdjusted hazard ratio 0.39 95% CI 0.31–0.50Authors' conclusion
In KTRs with T2DM, GLP-1 RAs use was associated with substantial reductions in all-cause mortality, MAKEs, and MACEs compared to nonuse without increasing complications. However, the underutilization of GLP-1 RAs represents a significant opportunity to improve post-transplant outcomes in this high-risk population.
Study context
- Population
- Adult kidney transplant recipients with T2D, TriNetX, January 1, 2006 to June 1, 2023; mean (SD) age 57.7 (12.2) years, 57.7% men9.8% used GLP-1 RAs
- Participants
- 35,488 recipients
- Exposure
- GLP-1 RA use within 3 months post-transplant vs nonuse
- GLP-1 RAs usersn = 3,564
- Outcome
- All-cause mortality
- Follow-up
- Median 2.5 years
Methodological detailspropensity score matching 1:1, TriNetX Global Collaborative Network
- Propensity score matching 1:1
- TriNetX Global Collaborative Network
Main finding
As reported in the abstract
Adjusted hazard ratio
0.39
95% CI 0.31–0.50
GLP-1 RAs usersvs Nonusers
aHR 0.39 (95% CI 0.31–0.50)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | aHR (95% CI) | |
|---|---|---|
| MACE · median follow-up 2.5 years | 0.66 (0.56–0.79) | |
| Major adverse kidney events (MAKEs) · median follow-up 2.5 years | 0.66 (0.58–0.75) | |
| 0.512Adjusted hazard ratio (log scale) |
Safety
Adverse effects
- Higher risks of nausea, vomiting and diarrhea
- Risks of suicide, hypoglycemia, retinopathy and pancreatitis not increased
Original publication
Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients. Cardiovasc Diabetol. Published 21 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →